Phase III trial of high-dose interferon alpha-2b versus cisplatin, vinblastine, DTIC plus IL-2 and interferon in patients with high-risk melanoma (SWOG S0008): An intergroup study of CALGB, COG, ECOG, and SWOG.

被引：0
|
作者：
Flaherty, Lawrence E.
Moon, James
Atkins, Michael B.
Tuthill, Ralph
Thompson, John A.
Vetto, John T.
Haluska, Frank G.
Pappo, Alberto S.
Sosman, Jeffrey Alan
Redman, Bruce G.
Ribas, Antoni
Kirkwood, John M.
Sondak, Vernon K.
机构：
[1] Wayne State Univ, Detroit, MI USA
[2] SW Oncol Grp, Ctr Stat, Seattle, WA USA
[3] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[4] Cleveland Clin, Cleveland, OH 44106 USA
[5] Seattle Canc Care Alliance, Seattle, WA USA
[6] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[7] ARIAD Pharmaceut, Cambridge, MA USA
[8] St Jude Childrens Res Hosp, Memphis, TN 38105 USA
[9] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[10] Univ Michigan, Ann Arbor, MI 48109 USA
[11] Univ Calif Los Angeles, Los Angeles, CA USA
[12] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA
[13] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8504
引用
收藏
页数：1
相关论文
共 50 条
  • [11] Randomized phase III trial of high-dose interferon alfa-2b (HDI) for 4 weeks induction only in patients with intermediate- and high-risk melanoma (Intergroup trial E 1697)
    Agarwala, S. S.
    Lee, S. J.
    Flaherty, L. E.
    Smylie, M.
    Kefford, R. F.
    Carson, W. E.
    Cohen, G.
    Kirkwood, J. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [12] A randomised phase II trial of 1 month versus 1 year of adjuvant high-dose interferon α-2b in high-risk acral melanoma patients
    Mao, Lili
    Si, Lu
    Chi, Zhihong
    Cui, Chuanliang
    Sheng, Xinan
    Li, Siming
    Tang, Bixia
    Guo, Jun
    EUROPEAN JOURNAL OF CANCER, 2011, 47 (10) : 1498 - 1503
  • [13] A randomized phase III trial of 1 month versus 1 year adjuvant high-dose interferon alfa-2b in patients with resected high risk melanoma
    Gogas, H.
    Dafni, U.
    Bafaloukos, D.
    Polyzos, A.
    Kokkalis, G.
    Kalofonos, H. P.
    Fountzilas, G.
    Skarlos, D.
    Tsoutsos, D.
    Pectasides, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [14] Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609
    Tarhini, Ahmad A.
    Lee, Sandra J.
    Hodi, F. Stephen
    Rao, Uma N. M.
    Cohen, Gary I.
    Hamid, Omid
    Hutchins, Laura F.
    Sosman, Jeffrey A.
    Kluger, Harriett M.
    Eroglu, Zeynep
    Koon, Henry B.
    Lawrence, Donald P.
    Kendra, Kari L.
    Minor, David R.
    Lee, Carrie B.
    Albertini, Mark R.
    Flaherty, Lawrence E.
    Petrella, Teresa M.
    Streicher, Howard
    Sondak, Vernon K.
    Kirkwood, John M.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06) : 567 - +
  • [15] A randomized phase II trial of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in high-risk acral melanoma patients.
    Si, L.
    Mao, L. L.
    Chi, Z. H.
    Cui, C. L.
    Sheng, X. N.
    Li, S. M.
    Tang, B. X.
    Guo, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [16] Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alfa-2b for high-risk melanoma patients using intergroup clinical trial data
    Kilbridge, KL
    Cole, BF
    Kirkwood, JM
    Haluska, FG
    Atkins, MA
    Ruckdeschel, JC
    Sock, DE
    Nease, RF
    Weeks, JC
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (05) : 1311 - 1318
  • [17] A phase II study of dacarbazine, cisplatin, interferon-alpha and high-dose interleukin-2 in 'poor-risk' metastatic melanoma
    Proebstle, TM
    Scheibenbogen, C
    Sterry, W
    Keilholz, U
    EUROPEAN JOURNAL OF CANCER, 1996, 32A (09) : 1530 - 1533
  • [18] Adjuvant treatment with pegylated interferon α-2a versus low-dose interferon α-2a in patients with high-risk melanoma: a randomized phase III DeCOG trialaEuro
    Eigentler, T. K.
    Gutzmer, R.
    Hauschild, A.
    Heinzerling, L.
    Schadendorf, D.
    Nashan, D.
    Hoelzle, E.
    Kiecker, F.
    Becker, J.
    Sunderkoeter, C.
    Moll, I.
    Richtig, E.
    Poenitzsch, I.
    Pehamberger, H.
    Kaufmann, R.
    Pfoehler, C.
    Vogt, T.
    Berking, C.
    Praxmarer, M.
    Garbe, C.
    ANNALS OF ONCOLOGY, 2016, 27 (08) : 1625 - 1632
  • [19] Intensified high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III melanoma: A randomized phase III Italian Melanoma Intergroup (IMI) trial [ISRCTN75125874]
    Chiarion-Sileni, V.
    Guida, M.
    Romanini, A.
    Ridolfi, R.
    Mandala, M.
    Del Bianco, P.
    Silvestri, B.
    Medici, M.
    Michiara, M.
    Dalla Palma, M.
    Puccetti, O.
    Pigozzo, J.
    Laveder, F.
    De Salvo, G. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [20] United States Intergroup E1609: A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon-α2b for resected high-risk melanoma.
    Tarhini, Ahmad A.
    Lee, Sandra J.
    Hodi, F. Stephen
    Rao, Uma N. M.
    Cohen, Gary Irvin
    Hamid, Omid
    Hutchins, Laura Fulper
    Sosman, Jeffrey Alan
    Kluger, Harriet M.
    Sondak, Vernon K.
    Koon, Henry B.
    Lawrence, Donald P.
    Kendra, Kari Lynn
    Minor, David R.
    Lee, Carrie B.
    Albertini, Mark R.
    Flaherty, Lawrence E.
    Petrella, Teresa M.
    Kirkwood, John M.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345